









Markets
/
Stocks
/
nasdaq-prof
/

Profound Medical Corp

PROF

6.190USD

-0.110-1.75%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

1.34MMarket Cap

LossP/E TTM



Profound Medical Corp

6.190

-0.110-1.75%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Profound Medical Corp

Currency: USD Updated: 2026-03-26

Key Insights

Profound Medical Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 75 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Profound Medical Corp's Score

Industry at a Glance

Industry Ranking

75 / 209

Overall Ranking

193 / 4546

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Profound Medical Corp Highlights

StrengthsRisks

Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 123.61% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 16.10M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 16.10M.

Overvalued

The company’s latest PE is -4.47, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 12.75M shares, decreasing 16.22% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.38.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

12.000

Target Price

+133.01%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of Profound Medical Corp is 7.42, ranking 74 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 5.98M, representing a year-over-year increase of 43.13%, while its net profit experienced a year-over-year increase of 65.25%.

Score

Industry at a Glance

Previous score

7.42

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.48

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.91

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.32

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.41

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Profound Medical Corp's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of Profound Medical Corp is 7.49, ranking 80 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -4.47, which is -40.44% below the recent high of -2.66 and -154.10% above the recent low of -11.37.

Score

Industry at a Glance

Previous score

7.49

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 75/209

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of Profound Medical Corp is 8.80, ranking 14 out of 209 in the Healthcare Equipment & Supplies industry. The average price target is 11.12, with a high of 12.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.80

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

12.000

Target Price

+133.01%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Profound Medical Corp

PROF

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of Profound Medical Corp is 7.36, ranking 37 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 7.93 and the support level at 4.74, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.02

Change

0.34

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.206

Neutral

RSI(14)

51.141

Neutral

STOCH(KDJ)(9,3,3)

65.956

Buy

ATR(14)

0.497

Low Volatility

CCI(14)

147.936

Buy

Williams %R

30.357

Buy

TRIX(12,20)

-1.004

Sell

StochRSI(14)

91.465

Overbought

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

5.772

Buy

MA10

5.611

Buy

MA20

5.922

Buy

MA50

6.720

Sell

MA100

6.862

Sell

MA200

6.147

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-26

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Investments Canada ULC

1.89M

Gagnon Securities LLC

1.73M

-0.96%

BDC Venture Capital

1.22M

Rosalind Advisors, Inc.

692.18K

Royce Investment Partners

Star Investors

859.91K

+12.42%

Timelo Investment Management Inc.

603.54K

-28.21%

Letko, Brosseau & Associates Inc.

986.25K

-18.10%

Gagnon Advisors, LLC

896.67K

Menawat (Arun Swarup Ph.D.)

637.05K

+2.15%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Profound Medical Corp is 3.00, ranking 133 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.58. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.